[HTML][HTML] Next steps toward eradication of hepatitis C in the era of direct acting antivirals

K Hesamizadeh, H Sharafi, MS Rezaee-Zavareh… - Hepatitis …, 2016 - ncbi.nlm.nih.gov
Results There are major steps that should be taken to eradicate HCV, including (1) the
development of screening strategies, particularly for groups such as intravenous drug users …

Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis

L Davoodi, B Masoum… - Experimental and …, 2018 - spandidos-publications.com
An estimated 185 million people worldwide are infected with hepatitis C virus (HCV).
Combination therapy with pegylated interferon‑α (peg IFN) and ribavirin is the first line of …

Navigating Evolving Challenges in Blood Safety

MR Pourkarim - Viruses, 2024 - mdpi.com
Blood safety remains a paramount public health concern, and health authorities maintain a
high level of vigilance to prevent transfusion-transmitted infections (TTIs)[1]. Rigorous …

Diagnostic approach to elucidate the efficacy and side effects of direct-acting antivirals in HCV infected patients

S Younas, H Mukhtar, UF Gohar, A Alsrhani… - The Journal of Infection …, 2021 - jidc.org
Introduction: The conventional interferon therapy of hepatitis C virus has been substituted
substantially with sofosbuvir and daclatasvir due to constraints in efficacy and tolerability …

[HTML][HTML] The course of hepatitis C infection and response to anti-viral therapy in patients with thalassemia major and hepatitis C infection: a longitudinal, prospective …

S Kamal, S Abdelhakam, D Ghoraba… - … journal of hematology …, 2019 - ncbi.nlm.nih.gov
Background The course of hepatitis C infection (HCV) in patients with thalassemia has not
been adequately studied, and management has not been optimized. The current …

WITHDRAWN: Low dose ribavirin for treatment of HCV infected thalassemia major patients: New indications for combination therapy

SV Tabatabaei, SM Alavian, M Keshvari, B Behnava… - 2010 - Elsevier
BACKGROUND & AIMS: Treatment guidelines contraindicate ribavirin for treatment of
hepatitis C virus (HCV) infection in thalassemia major patients. Nevertheless, the current …

The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors

F Zamani, H Ajdarkosh… - Indian journal of medical …, 2018 - Elsevier
Context: Patients with thalassaemia are at risk of infections such as hepatitis C virus (HCV)
due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients …

[PDF][PDF] Efficacy and safety of generic sofosbuvir/ledipasvir fixed-dose combination in Iranian patients with chronic hepatitis C virus infection

H Sharafi, M Nikbin, SH Alavian, B Behnava… - Hepatitis …, 2017 - brieflands.com
Background: Hepatitis C virus (HCV), as a global health concern, has infected around 1.6%
of the world population. Introduction of direct-acting antiviral regimens such as …

[HTML][HTML] Interferon lambda 4 polymorphism predicts sustained viral response in hepatitis C virus patients irrespective of hepatitis C virus genotypes, ethnicity or …

Q Wu, C Wang, EQ Chen, H Tang, ZZ Li, XZ Lei - Hepatitis Monthly, 2015 - ncbi.nlm.nih.gov
Results: Ten studies involving 4765 patients were included in the analysis. Of overall
studies, SVR was more frequent in TT/TT genotype compared to TT/ΔG+ ΔG/ΔG (OR= 4.439 …

Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study

FS Tameshkel, MHK Niya, B Amirkalali… - Archives of Medical …, 2022 - Elsevier
Background Treatment of Chronic Hepatitis C virus (HCV) infection in patients suffering from
hereditary β-thalassemia major is a concern due to drug complications and liver malfunction …